[Surgical treatment of recurrent Crohn's disease].

Acta Chir Iugosl

Institut za bolesti digestivnog sistema KCS, I hirurska klinika za digestivnu hirurgiju Beograd.

Published: July 1995

According to the literature, the incidence of Crohn's disease is 6.0:100,000, and the prevalence is 50.0-60.0:100,000. The prevalence in this countries 3.2:100,000 and the characteristics of the disease are: a more benign course, better prognosis and infrequent involvement of the colon. The incidence of recurrence is 40.0% during a 5 year period and 65% during a 10 year period. Practically, every patient operated for Crohn's disease will be reoperated once during the first five postoperative years. The experience of the authors indicates that the situation in this country is considerably better. During the period ranging from 1980-1992, a total of 70 patients were operated for Crohn's disease. In this group of operated patients 24 (34.40%) had recurrent symptoms. Seven patients (10.0%) in the series, operated at an earlier date at this Institution, were reoperated for Crohn's disease. Another 8 patients (11.43%) were also reoperated for Crohn's disease in this series, but their initial operation had been done at a different Institution (palliative or inadequate prior surgery). Indications for reoperation did not differ from indications for the initial operation: existence of surgical complications. The most important factors in the surgical management of recurrence are: assessment of disease activity and progression and adequate preoperative and postoperative nutrition in order to improve the immune response, which is often impaired by previous surgery, disease activity and inadequate management. Correct operative strategy is crucial. The authors, in both initial and reoperations, perform limited resection of the small intestine, generous resection of the large intestine and stricturoplasty and divergent stomas on the small intestine.(ABSTRACT TRUNCATED AT 250 WORDS)

Download full-text PDF

Source

Publication Analysis

Top Keywords

crohn's disease
20
disease
8
year period
8
operated crohn's
8
reoperated crohn's
8
initial operation
8
disease activity
8
crohn's
6
[surgical treatment
4
treatment recurrent
4

Similar Publications

Background: Adalimumab biosimilar MSB11022 (Idacio®) has been approved for the same indications as its originator (Humira®), based on findings from clinical trials in plaque psoriasis. Data on its efficacy and safety in inflammatory bowel disease, however, are scarce.

Methods: Retrospective, observational study of 44 patients with inflammatory bowel disease: 30 were treated with originator adalimumab, five were directly started on MSB11022, and nine switched from originator to biosimilar adalimumab.

View Article and Find Full Text PDF

Objectives: To analyze the CT imaging features of extranodal natural killer/T (NK/T)-cell lymphoma, nasal type (ENKTCL-NT) involving the gastrointestinal tract (GI), and to compare them with those of Crohn's disease (CD) and diffuse large B-cell lymphoma (DLBCL).

Materials And Methods: Data were retrospectively collected from 17 patients diagnosed with GI ENKTCL-NT, 68 patients with CD, and 47 patients with DLBCL. The CT findings of ENKTCL-NT were analyzed and compared with those of CD and DLBCL.

View Article and Find Full Text PDF

Background And Aims: The comparative efficacy of advanced therapies to improve health-related quality of life (HR-QoL) in Crohn's disease (CD) is unknown. We aimed to compare the impact of approved advanced therapies for moderate-to-severe CD on HR-QoL.

Methods: We searched MEDLINE, Embase, and Cochrane CENTRAL from inception to December 2023.

View Article and Find Full Text PDF

Background: The influence of environmental factors on the severity of early inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), is unclear. Herein, we aimed to investigate the role of environmental factors in the initial phenotype, activity, and severity of IBD.

Methods: Copenhagen IBD Inception Cohort is a prospective population-based cohort of patients with newly diagnosed IBD between May 2021 and May 2023.

View Article and Find Full Text PDF

Background And Aims: Prior studies indicate that serum calprotectin (SC) and plasma calprotectin (PC) can be used as biomarkers in Crohn's disease (CD). The aim of this study was to investigate the diagnostic accuracy of SC and PC in patients with a clinical suspicion of CD.

Method: This biobank study included patients from a prospective, blinded, multicenter study examining minimally invasive modalities for diagnosing CD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!